Abcam, ab240274, Anti-Acetylcholinesterase antibody [EPR18978] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Acetylcholinesterase antibody. Carrier free. Suitable for WB, IHC-Fr, IHC-P and reacts with Mouse, Rat samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR18978,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat,
Applications:WB, IHC-Fr, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab240274 is the carrier-free version of
ab183591
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Acetylcholinesterase also known as AChE is an enzyme with a molecular mass of approximately 67 kDa. It plays a critical role in neurotransmission by catalyzing the hydrolysis of the neurotransmitter acetylcholine into acetate and choline. This reaction occurs at neuromuscular junctions and cholinergic synapses therefore terminating synaptic transmission. AChE is highly expressed in muscle and brain tissue particularly in the synaptic cleft where it regulates the nerve signal terminations.
Biological function summary
Acetylcholinesterase is essential for maintaining neurotransmission dynamics by ensuring timely acetylcholine breakdown. It does not function as part of a larger enzyme complex but its activity is necessary for efficient synaptic signaling in the nervous system. This enzymatic action prevents continuous stimulation of muscles and nerves by rapidly degrading acetylcholine thereby ensuring proper muscle contraction and cognitive processes.
Pathways
Acetylcholinesterase participates significantly in the cholinergic system. It influences cholinergic signaling pathways by inactivating acetylcholine after its release into the synaptic cleft. This function aligns acetylcholinesterase closely with receptors like nicotinic and muscarinic acetylcholine receptors. It indirectly affects signal transduction pathways that involve these receptors with potential downstream effects on ion channels and intracellular messengers.
Acetylcholinesterase plays a significant role in Alzheimer's disease and myasthenia gravis. In Alzheimer's disease decreased acetylcholinesterase function can lead to accumulations of acetylcholine and disrupted signaling contributing to cognitive dysfunction. Acetylcholinesterase inhibitors are therapeutic in such contexts. For myasthenia gravis a disorder affecting neuromuscular transmission the enzyme’s interaction with antibodies targets synaptic acetylcholine receptors. This interaction results in weakened muscle contractions correlating with condition severity.